Teva Pharmaceutical Industries Ltd. (TEVA)
39.25
+0.53
(+1.37%)
USD |
NYSE |
Sep 15, 16:00
39.55
+0.30
(+0.76%)
Pre-Market: 05:20
Teva Pharmaceutical Industries Enterprise Value : 58.95B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 58.95B |
| September 14, 2026 | 58.33B |
| September 11, 2026 | 56.33B |
| September 10, 2026 | 55.57B |
| September 09, 2026 | 56.15B |
| September 08, 2026 | 56.05B |
| September 04, 2026 | 55.58B |
| September 03, 2026 | 55.89B |
| September 02, 2026 | 56.90B |
| September 01, 2026 | 55.38B |
| August 31, 2026 | 55.22B |
| August 28, 2026 | 55.68B |
| August 27, 2026 | 57.05B |
| August 26, 2026 | 57.40B |
| August 25, 2026 | 57.61B |
| August 24, 2026 | 56.25B |
| August 21, 2026 | 56.72B |
| August 20, 2026 | 56.11B |
| August 19, 2026 | 56.88B |
| August 18, 2026 | 55.84B |
| August 17, 2026 | 55.70B |
| August 14, 2026 | 56.06B |
| August 13, 2026 | 55.77B |
| August 12, 2026 | 56.03B |
| August 11, 2026 | 55.72B |
| Date | Value |
|---|---|
| August 10, 2026 | 55.33B |
| August 07, 2026 | 54.42B |
| August 06, 2026 | 53.78B |
| August 05, 2026 | 53.67B |
| August 04, 2026 | 53.33B |
| August 03, 2026 | 53.37B |
| July 31, 2026 | 54.01B |
| July 30, 2026 | 54.48B |
| July 29, 2026 | 53.66B |
| July 28, 2026 | 50.12B |
| July 27, 2026 | 49.43B |
| July 24, 2026 | 49.12B |
| July 23, 2026 | 49.55B |
| July 22, 2026 | 48.35B |
| July 21, 2026 | 49.75B |
| July 20, 2026 | 49.34B |
| July 17, 2026 | 50.54B |
| July 16, 2026 | 50.76B |
| July 15, 2026 | 49.99B |
| July 14, 2026 | 50.29B |
| July 13, 2026 | 50.71B |
| July 10, 2026 | 51.61B |
| July 09, 2026 | 51.78B |
| July 08, 2026 | 51.95B |
| July 07, 2026 | 53.59B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.116T |
| Bristol Myers Squibb Co. | 164.19B |
| RedHill Biopharma Ltd. | -- |
| Johnson & Johnson | 671.76B |
| MediWound Ltd. | 148.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -585.89M |
| Revenue (Quarterly) | 4.221B |
| Total Expenses (Quarterly) | 4.807B |
| EPS Diluted (Quarterly) | -0.5029 |
| Gross Profit Margin (Quarterly) | 52.07% |
| Profit Margin (Quarterly) | -13.88% |
| Earnings Yield | 1.52% |
| Operating Earnings Yield | 7.14% |
| Normalized Earnings Yield | 4.044 |